Jeff Jackson
Director, Evidence Strategy Lead Incyte Corporation
Jeff is Group Vice President, Translational Medicine at Incyte Corporation. Accountable for implementing translational research across the portfolio to enable both drug discovery and clinical development programs. This includes IND-enabling work, discovery and validation of biomarkers, dose selection, and companion diagnostics. Prior to joining Incyte in 2019, I spent 10 years at Bristol-Myers Squibb in various leadership roles across Oncology clinical development in both early clinical development and late clinical development for products including Opdivo, Yervoy, Sprycel, Empliciti, and Opdualag. Prior to BMS, I spent 17 years at GSK with various responsibilities in drug discovery and early clinical development, primarily in the Oncology therapeutic area.
Seminars
- Showcasing single-cell approaches for pharmacodynamics and proof-of-mechanism
- Reviewing advances in quantitative image analysis and multimodal models
